Novoheart Becomes Member of International Consortium Advancing Cardiac Safety in Drug Development

Novoheart announced today that it has become a member of the Cardiac Safety Technical Committee of the Health and Environmental Sciences Institute (HESI), an industry-led, international consortium including major pharmaceutical and biotechnology companies that aims to advance innovative approaches for early detection, prediction, and elimination of cardiac risk in drug development. Leveraging its established expertise in cardiac toxicity testing with its unique MyHeartTM Platform of bioengineered human heart tissues (including the world’s first “human heart-in-a-jar”), Novoheart’s membership on the Cardiac Safety Committee and active participation in related Working Groups positions the Company to help define future industry and regulatory standards for effective cardiotoxicity screening of all newly developed drugs.


For more detailed press release, please click here.

Subscribe To Our Newsletter

Fill out the following to subscribe and start receiving updates from us!